Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
__________________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
report (Date of earliest event reported) November 19,
2007
Neurologix,
Inc.
(Exact
Name of Registrant as Specified in Charter)
Commission
File Number: 000-13347
|
Delaware
|
|
06-1582875
|
|
(State
or other Jurisdiction of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
One
Bridge Plaza, Fort Lee, New Jersey 07024
(Address
of Principal Executive Offices)
(Zip
Code)
(201)
592-6451
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01. Other Events.
On
November 19, 2007, Neurologix, Inc.
issued a press release announcing the publication in the online edition of
the
Proceedings of the National Academy of Sciences additional results from
its Phase I trial for Parkinson’s disease. A copy of the release is attached
hereto as Exhibit 99.1.
The
information, including the exhibit
attached hereto, in this Current Report is being furnished and shall not be
deemed "filed" for the purposes of Section 18 of the Securities Exchange Act
of
1934, as amended, or otherwise subject to the liabilities of that Section.
The
information in this Current Report shall not be incorporated by reference into
any registration statement or other document pursuant to the Securities Act
of
1933, as amended, except as otherwise expressly stated in such
filing.
Item
9.01. Financial Statements and
Exhibits.
(d) Exhibits
99.1 Neurologix,
Inc. Press Release dated November 19, 2007.
SIGNATURES
Pursuant
to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report
to
be signed on its behalf by the undersigned hereunto duly
authorized.
| Date: November
20, 2007 |
|
|
| |
|
|
| |
|
|
| |
NEUROLOGIX,
INC. |
|
| |
|
|
|
| |
|
|
|
|
|
By:
|
/s/ Marc
L. Panoff |
|
| |
|
Marc
L. Panoff |
|
| |
|
Chief
Financial Officer,
Secretary and Treasurer |
|
| |
|
|
|